Hikal Ltd vs Medicamen Biotech Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Hikal Ltd is ₹ 189.85 as of 30 Apr 15:30 . The P/E Ratio of Hikal Ltd changed from 13.3 on March 2021 to 54.4 on March 2025 . This represents a CAGR of 32.54% over 5 yearsThe P/E Ratio of Medicamen Biotech Ltd changed from 53.8 on March 2021 to 86.2 on March 2025 . This represents a CAGR of 9.89% over 5 years The Market Cap of Hikal Ltd changed from ₹ 1769 crore on March 2021 to ₹ 4933 crore on March 2025 . This represents a CAGR of 22.76% over 5 yearsThe Market Cap of Medicamen Biotech Ltd changed from ₹ 652.37 crore on March 2021 to ₹ 612.46 crore on March 2025 . This represents a CAGR of -1.25% over 5 years The revenue of Hikal Ltd for the Dec '25 is ₹ 497.1 crore as compare to the Sep '25 revenue of ₹ 320.4 crore. This represent the growth of 55.15% The revenue of Medicamen Biotech Ltd for the Dec '25 is ₹ 47.44 crore as compare to the Sep '25 revenue of ₹ 47.54 crore. This represent the decline of -0.21% The ebitda of Hikal Ltd for the Dec '25 is ₹ 47.5 crore as compare to the Sep '25 ebitda of ₹ 9.1 crore. This represent the growth of 421.98% The ebitda of Medicamen Biotech Ltd for the Dec '25 is ₹ 4.91 crore as compare to the Sep '25 ebitda of ₹ 5.53 crore. This represent the decline of -11.21% The net profit of Hikal Ltd changed from ₹ 5.1 crore to ₹ -5.9 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Medicamen Biotech Ltd changed from ₹ 0.8 crore to ₹ 1.63 crore over 7 quarters. This represents a CAGR of 50.19% The Dividend Payout of Hikal Ltd changed from 18.52 % on March 2021 to 10.87 % on March 2025 . This represents a CAGR of -10.11% over 5 yearsThe Dividend Payout of Medicamen Biotech Ltd changed from 9.78 % on March 2021 to 13.45 % on March 2025 . This represents a CAGR of 6.58% over 5 years .

About Hikal Ltd

Hikal Limited, incorporated on July 8, 1988, has emerged as one of the preferred partners for global companies in segments such as pharmaceuticals, crop protection, animal health, biocides, and specialty chemicals.
The Company is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Company has 5 manufacturing facilities across three states in India.
It supply products to customers across the globe in the US, Japan, Europe, Canada, South East Asia, LATAM, India and RoW. Apart from this, it specialize in manufacturing APIs and intermediates in pharmaceutical division.
Within pharmaceutical division, it offer human health and animal health products. Hikal commenced its first project in 1991 at its first greenfield site at M.

About Medicamen Biotech Ltd

A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets.
The Company has presence over 35+ countries.
Its offerings include Finished Dosage Forms (FDF's) to African countries. In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market.
MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan).
The Company manufactures products across various therapeutic categories including Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic among others.

FAQs for the comparison of Hikal Ltd and Medicamen Biotech Ltd

Which company has a larger market capitalization, Hikal Ltd or Medicamen Biotech Ltd?

Market cap of Hikal Ltd is 2,340 Cr while Market cap of Medicamen Biotech Ltd is 343 Cr

What are the key factors driving the stock performance of Hikal Ltd and Medicamen Biotech Ltd?

The stock performance of Hikal Ltd and Medicamen Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Hikal Ltd and Medicamen Biotech Ltd?

As of May 4, 2026, the Hikal Ltd stock price is INR ₹189.85. On the other hand, Medicamen Biotech Ltd stock price is INR ₹253.3.

How do dividend payouts of Hikal Ltd and Medicamen Biotech Ltd compare?

To compare the dividend payouts of Hikal Ltd and Medicamen Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.